BRD4 and hepatocellular carcinoma: Epigenetic modifications are also being explored for MASLD‐HCC chemoprevention, as evidenced by bromodomain and extra terminal domain 4 (BRD4) inhibitors, which significantly reduced tumor progression in MASH‐HCC models.115